Vega Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Vega Therapeutics, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT07115004
- Locations
- 🇺🇸
Science 37, Inc. (Virtual Clinical MetaSite), Morrisville, North Carolina, United States
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Vega Therapeutics, Inc
- Target Recruit Count
- 116
- Registration Number
- NCT05776069
- Locations
- 🇺🇸
Orthopedic Institute for Children (UCLA), Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
News
No news found